Department of Pathology, Radboud University Medical Center, P.O. Box 9101, 6525 GA, Nijmegen, Netherlands.
University of Bern, Bern, Switzerland.
Virchows Arch. 2021 Sep;479(3):459-469. doi: 10.1007/s00428-021-03059-9. Epub 2021 Mar 1.
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet methods for its assessment have varied widely. In an effort to standardize its reporting, a group of experts met in Bern, Switzerland, in 2016 to reach consensus on a single, international, evidence-based method for tumor budding assessment and reporting (International Tumor Budding Consensus Conference [ITBCC]). Tumor budding assessment using the ITBCC criteria has been validated in large cohorts of cancer patients and incorporated into several international colorectal cancer pathology and clinical guidelines. With the wider reporting of tumor budding, new issues have emerged that require further clarification. To better inform researchers and health-care professionals on these issues, an international group of experts in gastrointestinal pathology participated in a modified Delphi process to generate consensus and highlight areas requiring further research. This effort serves to re-affirm the importance of tumor budding in colorectal cancer and support its continued use in routine clinical practice.
肿瘤芽殖是结直肠癌中长期确立的独立不良预后标志物，但评估其的方法差异很大。为了规范其报告，一组专家于 2016 年在瑞士伯尔尼开会，就肿瘤芽殖评估和报告的单一、国际、基于证据的方法达成共识（国际肿瘤芽殖共识会议 [ITBCC]）。使用 ITBCC 标准进行肿瘤芽殖评估已在大量癌症患者队列中得到验证，并纳入了几项国际结直肠癌病理和临床指南。随着肿瘤芽殖的更广泛报告，出现了需要进一步澄清的新问题。为了让更多的研究人员和医疗保健专业人员了解这些问题，一群国际胃肠道病理专家参与了一项改良 Delphi 流程，以达成共识并强调需要进一步研究的领域。这一努力再次肯定了肿瘤芽殖在结直肠癌中的重要性，并支持其在常规临床实践中的持续应用。
